Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Q1 2025 Earnings Call Transcript
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Q1 2025 Earnings Call Transcript May 8, 2025Ligand Pharmaceuticals Incorporated beats earnings expectations.
Ligand Pharmaceuticals Inc (LGND)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period: Filing is Ongoing
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Impax Asset Management Ian Simm | 280,208 | $29,461,069 | 0.18% | |
| 2. | Royce & Associates Chuck Royce | 0 | $0 | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $97.39 | 2,500 | Officer, Director | 123,010 | 2024-08-08 | Filing | |
| $59.38 | 4,000 | Officer, Director | 73,090 | 2023-09-22 | Filing | |
| $82.76 | 2,500 | Officer | 173,354 | 2022-05-13 | Filing | |
| $82.52 | 1,000 | Director | 28,190 | 2020-11-02 | Filing | |
| $87.01 | 750 | Director | 67,203 | 2019-09-03 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $115.03 | 5,000 | Officer | 18,879 | 2025-03-04 | Filing | |
| $116.37 | 2,104 | Officer | 20,647 | 2024-12-23 | Filing | |
| $123.65 | 2,406 | Director | 29,515 | 2024-11-27 | Filing | |
| $99.60 | 2,000 | Officer | 22,534 | 2024-09-23 | Filing | |
| $103.95 | 800 | Officer | 24,610 | 2024-09-20 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 2,920,235 | $307,033,510 | 0.01% | |
| 2. | 2,055,732 | $216,139,663 | 0% | |
| 3. | 642,712 | $67,574,740 | 0.51% | |
| 4. | 607,222 | $63,843,321 | 0.92% | |
| 5. | 554,517 | $58,301,951 | 1.65% |
News See All
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Q4 2024 Earnings Call Transcript
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Q4 2024 Earnings Call Transcript February 27, 2025Ligand Pharmaceuticals Incorporated misses on earnings expectations.
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Q3 2024 Earnings Call Transcript
Operator: Good morning. My name is Aaron, and I will be your conference operator for today. At this time, I would like to welcome everyone to the Ligand's Third Quarter 2024 Earnings Call.
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Q2 2024 Earnings Call Transcript
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Q2 2024 Earnings Call Transcript August 6, 2024Ligand Pharmaceuticals Incorporated misses on earnings expectations.
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Q1 2024 Earnings Call Transcript
Ligand Pharmaceuticals Incorporated beats earnings expectations. Reported EPS is $4.75, expectations were $1.13.
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Q4 2023 Earnings Call Transcript
Ligand Pharmaceuticals Incorporated beats earnings expectations. Reported EPS is $1.03, expectations were $0.58.
13 Most Promising Small-Cap Stocks According to Analysts
In this piece, we will take a look at the 13 most promising small-cap stocks according to analysts.
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Q3 2023 Earnings Call Transcript
Operator: Thank you for standing by. My name is Danika and I'll be your conference operator today. At this time, I'd like to welcome everyone to the Ligand Third Quarter 2023 Earnings Webcast.
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Q2 2023 Earnings Call Transcript
Operator: Thank you for standing by. My name is Brian, and I will be your conference operator today. At this time, I would like to welcome everyone to the Ligand Second Quarter 2023 Earnings Webcast.
Top 12 Small-Cap Stocks With Highest Upside Potential
In this piece, we will take a look at the top 12 small-cap stocks with the highest upside potential.
Billionaire Hedge Funds
